HC Wainwright & Co. maintains Tyra Biosciences at Buy, lowers price target to $27 from $29
HC Wainwright & Co. kept its Buy rating on Tyra Biosciences but reduced its price target to $27 from $29, a 6.9% decrease. The new target suggests a 28.6% upside from the Nov 10 close of $21.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short‑term selling pressure.
Market read
Analyst price‑target cuts are a common catalyst for micro‑cap moves; traders may adjust positions accordingly.
What to watch
Upcoming clinical trial data could offset the target reduction.
Background
The article reports a recent analyst rating action on Tyra Biosciences.
Ticker impact
HC Wainwright lowered its price target on Tyra Biosciences to $27 from $29.
likely downward pressure as the market prices in the lower target
A price‑target cut is a direct negative catalyst, especially for a micro‑cap biotech where analyst opinions move price.
Market effects
May slightly dampen sentiment in the small‑cap biotech sector.
Limited to U.S. biotech investors.
Low
Counterpoint
Some investors may view the cut as an opportunity if they believe the stock is undervalued.
Key entities
- AnalystHC Wainwright & Co.
Equity research firm that issued the price‑target change.
- CompanyTyra Biosciences
Biotech firm whose stock is affected.

